Editas Medicine (EDIT) Posts Smaller Q3 Loss

Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.32), $0.34 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $14.52 million versus the consensus estimate of $9.83 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
• Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral